°øÁö»çÇ×

³»¿ëºÐ·ù Á¤±â¼¼¹Ì³ª
°Ô½ÃÀÚ PGRC ()
Á¦¸ñ [PGRC]±Ý¿ä Àú³ÎŬ·´ °øÁö(2016/10/21)
ÂüÁ¶URL  ÂüÁ¶URL Á¤º¸¾øÀ½.
ÂüÁ¶ÆÄÀÏ  ÆÄÀϾøÀ½
³»¿ë
¾à¹°À¯Àüü¿¬±¸¼¾ÅÍ¿¡¼­´Â ´ÙÀ½°ú °°Àº ³»¿ëÀ¸·Î ¼¼¹Ì³ª¸¦ °³ÃÖÇÕ´Ï´Ù.
°ü½É ÀÖ´Â ±³¼ö´Ô, ¿¬±¸¿ø ¿©·¯ºÐÀÇ Àû±ØÀûÀÎ Âü¿© ¹Ù¶ø´Ï´Ù.

1) Àú³ÎŬ·´ ¿¬Á¦
- Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race.
- Moxifloxacin is a potent in vitro inhibitor of oct- and mate-mediated transport of metformin and ethambutol.

2) Àú³ÎŬ·´ ¿¬ÀÚ
- Á¤ÇýÀº  / Á¶¼±¾Æ ÀÓ¼öÁ¤ Â÷Àº¿µ
- Parvez / Nazia ÃÖ¿µ°æ ½ÅÈ£Á¤

3) ÀÏ ½Ã : 2016³â 10 ¿ù 21 ÀÏ (±Ý) ¿ÀÈÄ 4½Ã ~ 5½Ã

4) Àå ¼Ò : Àǰú´ëÇÐ 805È£